Get the Stockscreener App
266.67
1.04%
1.46
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $266.67, with a volume of 561.25K.
It is up +1.04% in the last 24 hours and up +1.13% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$265.21
Open:
$266
24h Volume:
561.25K
Relative Volume:
0.09
Market Cap:
$471.27B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
131.53
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+2.08%
1M Performance:
+1.13%
6M Performance:
+30.76%
1Y Performance:
+20.37%
1-Day Range:
$265.05
$269.39
1-Week Range:
$260.88
$269.39
52-Week Range:
$190.75
$269.39
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
266.69 | 468.66B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,161.88 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.36 | 648.72B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
148.71 | 372.32B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.73 | 268.53B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie (ABBV) Receives a Buy from Scotiabank - The Globe and Mail
AbbVie stock closes at USD 265.21 as EU approval adds support - AD HOC NEWS
Why is AbbVie (NYSE:ABBV) in focus amid today’s healthcare stocks discussion? - Kalkine Media
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis - Yahoo! Finance Canada
Where does AbbVie (NYSE:ABBV) go as medicine launches shifts? - Kalkine Media
AbbVie stock gains 0.3 percent ahead of the open - AD HOC NEWS
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Pediatric Arthritis Treatments: AbbVie Expands RINVOQ to Children With Active pJIA - Trend Hunter
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters - Yahoo Finance
AbbVie stock ends the day higher at USD 265.51 - AD HOC NEWS
AbbVie’s Rinvoq Wins 11th EU Approval in Pediatric Arthritis - AskTraders
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis - Yahoo Finance
New EC approval for AbbVie’s Rinvoq - The Pharma Letter
Is AbbVie (NYSE:ABBV) Stock Worth Watching Today? - Kalkine Media
AbbVie receives EU approval for RINVOQ juvenile arthritis treatment - grafa.com
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach - AbbVie News Center
AbbVie vs. Pfizer: Which is the Better Dividend Investment? - Intellectia AI
AbbVie Secures EU Approval for Rinvoq in Juvenile Arthritis - Yahoo Finance
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? - The Globe and Mail
ADARx sets $350 million IPO terms as AbbVie lines up a stake - The Pharma Letter
AbbVie’s Rinvoq gains EU approval for juvenile arthritis - Investing.com
European green light for AbbVie's Rinvoq pediatric expansion - marketscreener.com
AbbVie’s Rinvoq wins EU approval for pediatric arthritis - Investing.com
AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis - Investing News Network
Key facts: AbbVie, Inc. $600M China outlay; House seeks trial files; 4.9% ADARx - TradingView
AbbVie Inc. stock rises 0.7 percent ahead of the open - AD HOC NEWS
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV) - The Globe and Mail
AbbVie stock ends the day slightly higher at the close on Nasdaq - AD HOC NEWS
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on - reuters.com
What’s Really Driving AbbVie (NYSE:ABBV) Beyond Healthcare Demand? - Kalkine Media
Drug developer ADARx seeks $1.74 billion valuation in US IPO - reuters.com
AbbVie partners with Iambic to apply AI to small molecule drug discovery - The Pharma Letter
Pete Sessions from Texas’s 17th Congressional District Sells Shares in AbbVie and Alphabet - Investing.com
Rep. Pete Sessions Has Sold Up to $100K Worth Of AbbVie Stock: Here’s What You Should Know - Benzinga
Iambic releases next version of its Enchant model, signs deal with AbbVie - Endpoints News
ABBV Looks 19.5% Overvalued on GF Value™ - GuruFocus
AbbVie Inc. stock gains on new AI drug discovery collaboration with Iambic - AD HOC NEWS
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery - Investing News Network
AbbVie Inc. (ABBV) Enters Multi‑Year AI Drug Discovery Collaboration With Iambic - TradingView
AbbVie Inc. (ABBV) Stock Analysis: Navigating Growth With A 5.55% Upside Potential - DirectorsTalk Interviews
AbbVie stock heads into the open after a flat September 18, 2026 close - AD HOC NEWS
AbbVie Inc. stock holds firm as dividend and pipeline support valuation - AD HOC NEWS
AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield - Yahoo Finance
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® at Psych Congress 2026 - Investing News Network
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie Stock Just Posted a 74% Response Rate in Myeloma. Here’s What It Means for the Stock in 2026 - Yahoo Finance
AbbVie (ABBV) Could Be 4% Undervalued After Phase 3 Trial Wins - simplywall.st
AbbVie Q2 2026 Earnings: EPS Slightly Misses Estimates as Stock Holds SteadyEarnings Surprise Stocks - careplusvn.com
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting - Yahoo Finance
What Happens To AbbVie Stock If SKYRIZI Slows Down? - Trefis
AbbVie (ABBV) Stock Looks Undervalued On Future Cash Flow - Yahoo Finance
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):